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Biotechnology is the term for the techniques of managing biological systems for human 
benefit. [ 1] A biological system can range from a single cell organism to different types 
of plants, animals, and to the very complicated human being. Biotechnology includes a 
great range of scientific and technological disciplines and has a great variety of important 
applications in biology, medicine, agriculture, and various industries. In our report, we 
shall only focus on one of the most active frontiers of today's biotechnology-human 
genom1cs. 
I. Human Genomics And Some Related Basic Concepts 
To understand what human genomics is, it is necessary to introduce some basic 
terminologies and concepts first. 
1. Cell 
Cell is the basic unit of all life. Namely, all living things are made of cells. [1] A typical 
human body contains several trillions of cells of different types, such as skin cells, nerve 
cells, blood cells, and muscle cells. All cells are enclosed by a thin covering, called 
membrane. Inside the membrane, most cells in a human body have two main parts: a 
core, called nucleus, and the rest outside the nucleus, called cytoplasm. Figure 1 depicts a 
typical cell. 
Cells can divide and become more cells. This replication contributes to both gro\\ih and 
the rejuvenation of the body. The trillions of cells now in your body have developed from 
just a single cell. If your memory ever fades, you know that cells can also die. 
2. Chromosome 
Inside the nucleus of a typical human cell, there are 46 (23 pairs) thread-like structures 
called chromosomes. Human chromosomes contain two sets, one from each parent. Each 
set has 22 autosomes and an X or Y sex chromosome. A female has a pair of X 
chromosomes, and a male has an X and Y pair. Figure 1 also shows the chromosomes in 
the nucleus. 
3. DNA (deoxyribonucleic acid) 
Chromosomes roughly contain even parts of protein and DNA. In a chromosome, two 
DNA strands are twisted together to form an entwined spiral, called double helix, as 
shown in Figure 2. 
At a more basic level, each DNA strand is a polymer of repeating nucleotides. Each 
nucleotide consists of a simple sugar, a phosphate group, and one of the four nitrogenous 
bases - adenine (A), thymine (T), cytosine (C), and guanine (G). [2] 
Weak bonds between complementary bases, A-T and G-C, hold the two DNA strands 
together. Each of these linkages is called a base pair (bp ). It is this specific base pairing 
that ensures the replication of DNA. As you can image, unzipping the double helix 
provides unambiguous templates for producing exact copies of the original DNA. 
The particular order of bases in a DNA strand is called the DNA sequence. 
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Figure 1. Illustration of a cell and its fine structure. 
The exact amount of each of the nucleotides and the precise order in which they are 
arranged is unique for each kind of living thing and for each individual in a particular 
type of species. It is this DNA sequence that spells out the exact instructions required to 
create a unique individual with his or her own traits. In a human cell, there are about 3 
billion base pairs. 
4. Gene 
A gene is a specific sequence of nucleotides in a DNA that encodes instructions on how 
to make a protein. At the molecular level, genes are responsible to synthesizing proteins 
in a human cell that determine all personal features such as sex, height, color of the eyes, 











Figure 2. Illustration of a double-helix DNA 
It was just less than two years ago when scientists found that there are about 30,000 -
40,000 genes in a human cell. [3] An average gene consists of ~3,000 bases. Therefore, 
genes only count for approximately 2% of the DNA. [3] 
5. Genome and genomics 
The genome is an organism's complete set of DNA. The human genome is the full 
complement of the DNA in the 23 pairs of chromosomes, or the approximately 3 billion 
base pairs in a human cell. The genome is the master blueprint of all actions during the 
lifetime of a cell. It is the complete set of code of life. Human genomics is the study of 
the entire human genome. The very first step is to find the precise sequence of the 3 
billion base pairs in a human cell. 
II. Human Genomics and The Human Genome Project (HGP) 
The genetic revolution has its beginnings about a century ago with the rediscovery of 
Gregor Mendel's "transmission of characters in pea plants" [4] in 1859. His first 
generation hybrid's fertile and large tasty seed characteristics were reproduced the 
following year. 
In the 1953, James Watson and Francis Crick discovered the structure of 
deoxyribonucleic acid (DNA), the molecule of heredity, to be in a double helix form. [5] 
This breakthrough directed focus on bio-molecular inheritance and cellular function. 
With the DNA structure revealed, scientists had the beginnings of new questions, 
possibilities and research to learn how the genes of life forms (plants, animals and 
humans) evolve, interact, react, exchange information, live and die as complex 
organisms. 
In the mid-1980's, Department of Energy (DOE) first initiated the effort of mapping the 
entire human genome. National Institute of Health (NIH) then joined in the 1990s to form 
and coordinate the US Human Genome Project. Now, the HGP collaboration involves 20 
groups from the United States, the United Kingdom, Japan, France, Germany and China 
to produce a draft sequence of the human genome [6]. 
"The project originally was planned to last 15 years, but rapid technological 
advances have accelerated the expected completion date to 2003. Project goals 
are to 
• identify all genes in human DNA, 
• determine the sequences of the 3 billion chemical base pairs that make up 
human DNA, 
• store this information in databases, 
• improve tools for data analysis, 
• transfer related technologies to the private sector, and 
• address the ethical, legal, and social issues (ELSI) that may arise.from 
the project. 
To help achieve these goals, researchers also are studying the genetic makeup of 
several nonhuman organisms. These include the common human gut bacterium 
Escherichia coli, the fruit fly, and the laboratory mouse." [6] 
International Human Genome Sequencing Consortium, primarily funded by US 
government, makes their findings to the public for the benefit of the entire world. In 
2001, this consortium published the draft of DNA sequences of the human genome in a 
paper entitled "Initial Sequencing and analysis of the human genome." [3] 
One of HGP's initiatives was to disseminate its finding to the private sector, educational 
institutions and other governmental systems. "By licensing technologies to private 
companies and awarding grants for innovative research, the project is catalyzing the 
multibillion-dollar U.S. biotechnology industry and fostering the development of new 
medical applications" [6]. 
In the private sector, Celera Genomics, a company led by J.C. Venter, took a slightly 
different and faster approach to DNA sequencing. Celera's business model is based on 
selling its genomic expertise and database to identify pharmaceutical objectives, assist in 
drug designs targeting specific diseases, and minimize drug side effects. Celera was also 
able to produce a draft of DNA sequences of the human genome and published its results 
in February 2000. [7] The two versions of human genome maps agree well with the 
Celera' s draft having slightly more details. Aach et al compared the two human genome 
maps. [8]. It is worth noting that Celera has the full access of the HGP's data while its 
own data is less freely available to the public. 
To date, Celera and International Human Genome Sequencing Consortium are still in 
competition to produce the first high quality DNA sequence of human genome by 2003. 
In addition to human genome, the International Human Genome Sequencing Consortium 
is also sequencing many forms of viruses, bacterium, some plants and animals, plus some 
human bacterium, in hope to learn more by comparison and to find more applications. 
The "draft sequence data are mostly in the form of 10,000 base pair-sized fragments 
whose approximate chromosomal locations are known" [6]. The finished high quality 
sequence is 63% completed with the goal of 100% completion by 2003. What's left is to 
close gaps, reduce ambiguities and achieve a high quality DNA sequence with no more 
than one error for every 10,000 bases. The finished sequences that have been completed 
for the human chromosomes are: 5, 16, 19, 20, 21 and 22. [6] 
With the constant upcoming of new information, our understanding of living organisms, 
including human life, keeps changing. New sciences are created and new technologies 
are needed to support or refine the genome science. Focus is now on "increasing our 
ability to prevent, treat and diagnose disease, to engineer new life forms for food and 
medical uses; and, ultimately, creating the ability to replace or correct detrimental genes" 
[6]. 
With continued research and refinement, understanding the genome may "resolve which 
human characteristics are innate or acquired and how the interplay between heredity and 
environment contributes to defining susceptibility to illness. Such an understanding will 
make it possible to study how genomic DNA varies among patient groups, and especially 
the role of such variation in the causation of important illnesses and responses to 
pharmaceuticals'' [ 6]. 
III. The Impacts And Anticipated Benefits Of Human Geno mies 
The human genome project has a goal of producing a high quality set of DNA sequence 
data in 2003. Unprecedented details for human genome information will become 
available in the very near future. Much more about human genomics still remains to be 
discovered. Even today, the significant impacts of human genomics can already be seen. 
1. Impact on the science of human biology 
The human genome project will provide the entire map of DNA sequence in a human 
cell. With all genes in a human cell being identified, our understanding of human genetics 
will be pushed to the molecular level at its entirety. The complete DNA sequencing will 
provide a base for understanding human biology. It will change the way of biological 
research. With the entire DNA sequence, scientists can approach questions systematically 
by studying all of the genes in a genome. In the past, researchers were only able to study 
a few genes at a time . 
. In the decades to come, we shall be able to search for answers, at the molecular level, of 
profound questions such as, how we develop from an embryo to adult, how human being 
work biologically, and what are the causes when things go wrong in our body. Genomics 
will undoubtedly move the science of biology into a new height. 
Furthermore, the progress in human genomics has been creating new branches of science. 
For example, the complete sequence of approximately three billion base pairs is a 
massive quantity of data. The need for handling biological data with computer science 
and information technology gave birth to bioinformatics to manage and analyze this data. 
Proteomics is another new branch of science that is the study of protein expression and 
function. After all, genes only store the blueprint of life but genes are "lifeless." Proteins 
are the products of genes and they carry out the primary functions of a cell in response to 
intra-cellular and extra-cellular signals. The proteins exhibit what life really is. 
2. Impact on medicine [9] 
Even though it still sounds like a fairy tale, human genomics will ultimately provide 
detailed information how all genes function normally or abnormally. Such knowledge 
will revolutionize medicine. Instead of treating the symptoms of a disease, the new era of 
molecular medicine will pinpoint specific genes for the cause of a disease by gene tests. 
Once the gene with problems is identified, a disease can be treated by replacing the 
defective gene by gene therapy. It is also possible to use highly targeted pharmaceuticals 
produced based on human genomics to directly cure the disease at its molecular 
foundations (pharmacogenomics ). 
(1 ). Gene tests: The ultimate gene tests should include the full DNA test of a 
patent and a library of DNA data of family members, relatives and others. Such a gene 
test will pinpoint the defective genes responsible for the patent's disease utilizing the data 
bank. It will be the ultimate diagnostic tool for any disease. 
At its current level, gene testing is still immature. Nevertheless, various DNA-based tests 
can be used with some uncertainty to diagnose a disease, confirm a diagnosis, or predict a 
future disease in a healthy individual. For example, some gene tests can detect mutations 
associated with specific genes relevant to colon cancer in some patents. Even with severe 
limitations, these tests can currently be used to make risk estimates in presymptomatic 
individuals with a family history of the disorder. It is only a matter of time for more tests 
and more accurate tests become available. 
(2). Gene therapy: Gene therapy, or gene transfer, is to replace "bad" genes with 
normal genes. It is still in its very early stage although it is already very controversial 
ethically. Nevertheless, it holds the potential to treat or cure disease or enhance particular 
traits. Currently, gene therapy serves as a clinical trial for giving some participating 
patents the last chance of survival. 
(3). Pharmacogenomics: Pharmacogenomics is a new branch of science that 
blends pharmacology with human genomics. Its goal is to correlate DNA variants with 
individual responses to medical treatments and to customize drugs for such individuals. 
Human genomics will provide detailed information on particular genes of a group of 
individuals for a disease. Such right-on-the-target information will lead to new drugs 
specifically designed for such a disease. These highly targeted drugs will not only have 
high efficiency to cure the particular disease, but also eliminate or reduce side effects and 
adverse reactions that kill more than 100,000 people each year. 
3. Impacts on other fields 
Progress in Human genomics will have to be accompanied by progress in genomics of 
other biological systems. As current frontier medical research is often first done on 
animals rather than human beings, results in genomics of other biological systems will be 
useful to human genomics. Furthermore, genomics of animals, plants, and microbials 
have theirs own significance as well, such as [9] 
(1 ). Breeding healthier, more productive, disease-resistant farm animals, 
(2). Growing disease-, insect-, and drought-resistant crops, 
(3). Growing more nutritious produce, 
( 4 ). Incorporating edible vaccines into food products, 
(5). Developing new energy sources (biofuels), and 
(6) Developing new cleanups for toxic waste. 
With commercial incentives, the development of genomics of other species seems to get 
exotic. It was reported recently that Fugu (puffer fish), a Japanese Sushi delicacy, will be 
sequenced. [l 0] Fugu, a Sushi delicacy, enjoyed by thousands particularly in Japan, also 
claims about 100 diners' lives every year from its highly potent neurotoxin when 
prepared improperly. It is the only food forbidden to be served to Japan's royal family. 
May the emperor ofDa Nippon enjoy Fugu one day! 
IV. Ethical Issues 
Human genomic technology's greatest obstacle may be the ethical acceptance and 
regulated use by the public. Having a globally accepted governing set of laws, 
regulations, guidelines and disciplining actions is an impossibility. Even nationally, this 
is a challenging task. Despite the differences in religion, politics, and social groups, 
biotechnology and its implications, especially in the human genome aspect, will continue 
to advance. What is needed is a managing mechanism to guide and direct the human 
genome application. 
Since this is a new field with so many unknowns, caution must be used in the application 
of old laws and ideologies in maintaining a healthy progressive balance between science 
and humanity for the near future. Yet, hindsight is a good starting point to anticipate 
possible ethical confusion and ineffective regulations. These issues have to be addressed 
in depth before social and regulatory factions play catch up in the wake of genomic 
havoc. 
Currently still in its infancy, genetic coding is still a developing science. There are 
relatively safe assumptions being made, but time and continued research will validate or 
dispute these assumptions. Presently, caution should accompany the genetic information 
used for diagnosing or treating ailments. Stigmatism, mental health, employment and 
institutional acceptance are all serious concerns, should erroneous hereditary information 
be made use of. 
An important aspect of this new field is the continued physician-patient relationship. Part 
of the physician's duty is to respect and maintain the patients' confidence in treatment 
and personal information. With genetic tools, physicians will be able to provide more 
effective care, treatments and cures with minimal side effects. But the genetic 
information gathered could have negative implications for the patient and their genetic 
relatives. What is at stake here is the ownership and proper dissemination of the genetic 
data. 
The balance of private verS~s public best interests lies on the shoulders of the physicians. 
Arbitrary laws that are enforced by removed governing bodies compound this juggling. 
Patient expectations ansf trust are important for the physicians to remain in business. The 
public's interests and safety are paramount as well. But where the two equally meet, may 
never satisfy all effected parties. 
A question for genetic advancement is, to treat or not to treat? Which is more valuable, 
individual treatment or public welfare? There is a need for public protection and 
individual care. Those threatened of exposure may forego medical treatment or withhold 
information about their conditions. The practice of medicine and the physician's duty is 
to provide care, treatment and if possible, a cure to ailments. The physician, individual 
and the public's economic and social wellness may be jeopardized without a firm hand to 
guide and protect each best interest while advancing the knowledge and science 
technology of human genome. 
At this time, we cannot escape our genes. What is needed is continued accuracy in 
isolating and treating detrimental genes. Currently, genetic coding can only tell of risks 
and limited certainties. We have inherent factors that may or may not develop in our 
lifetime. With irreversible advances to be made in the genetic progress and its 
accompanying technology, there may come a time when we can escape our genes. 
V. Legal Issues 
The current arbitrary laws have to be more solidified to gain public and private 
acceptance of utilizing and disseminating genetic information gained by new and 
upcoming technology. Patient confidentiality is being eroded by lawsuits and third party 
inquiries for physicians to disclose patient information. In modem history, laws have 
been created that forces physicians to disclose info under such patient acts of breachrnent 
(contract and fiduciary), invasion of privacy, violation of statutes and the United States 
Constitution [10]. More recent mandatory disclosures include sexually transmitted 
diseases, violent tendencies and gunshot wounds among other seemingly public right-to-
knows. These have all led to a sense of subjective set of laws concerning disclosure of 
medical information. The impacts of this have yet to be felt with genetic information to 
be gained through genome technology. 
The current situation is not a suitable foundation to handle genetic information. \Vhat is 
needed is set regulations with little room for changes. These would only be effective if it 
is known under what circumstances a physician must disclose genetic information about 
their patients. If all parties are aware of these immovable guidelines, then all know 
where they stand and the consequences of their decisions. 
Proper regulations need to be addressed before the time comes where they have to be 
reassessed in order to fix loopholes and conflicting legal issues. Past failures and 
historical solutions have to be reviewed and applied to a new arena. \Vhat is not ideal is 
having a limited number of like-minded people making the rules or interpreting them. 
Strategies for addressing Issues: 
Here are two generic ways of addressing the ethical and legal issues, externally and 
inte~ally, created by human genome technology. By looking from the outside of the 
practice of medicine, autonomy and social responsibilities can be addressed [I I]. 
The benefits and harms to patients and the public must be weighed. Fairness in 
distribution of available health remedies gives weight to individual protection. But social 
awareness of uncontrolled health and safety risks is equally important. Through 
increased capability for treatment and preventative measures, there is a sense of social 
responsibility to see that all are allowed equal opportunity to receive proper medical 
attention, even at the risk of some unchangeable diagnosis going unnoticed. 
The social responsibility amounts to public protection, a sensitive yet important 
safeguard. The health of relatives and business success may depend on genetic 
disclosure. But also to be kept in mind is that in the past, without genetic information, 
society moved on without fearing about their neighbors' inherent possibilities. This 
molehill should not be generated into a mountain. Boundaries have to be concrete in 
what and how much genetic information should be disseminated. These boundaries will 
help control the technological directions of genetic science. 
These issues should also be viewed internally with regards to the practice of medicine 
around genetic information. Curing, caring and the patient's right to secrecy and their 
right to disclosure of their personal genetic information should remain at the forefront of 
medicine. Continued medical research in the human genomic arena will only enhance 
these virtues. Genetic advances and treatment will be far broader if there is adequate and 
reliable individual protection yet with a vested interest in public welfare. 
In both, the benefits and harms to the individual and their rights should be weighed 
against the potential benefits and harms of society. The bottom line is that genetic 
information is about an individual's personal being and those aspects should be weighted 
more heavily. The benefits of medical care outweigh potential harm to the public. What 
gain is there if people do not feel safe in exposing themselves to a system without 
protection. 
VI. The Future 
The "information era," even though many people have yet to fully understand and come 
to grips with being completely immersed in it, is going to be replaced by the emerging 
biotechnology. Biotechnology is showing great promise to become the next economic 
era. This "bio-economy" has already started, even though very few people have seen 
direct impacts of this new technology. 
Genomics tells us who human beings are, not where they should go. What is being 
learned from the study of genomics is radically changing the how people think and 
perceive themselves and their place in the natural world. It is leading to conclusions that 
all species stem from the same ancient common ancestors. The future will soon show 
even clearer lineages as molecular archeologists study the genome sequences that are 
becoming available. [12] 
Within a few years from now, testing a couple of drops of blood from a newborn will be 
able to provide a "fate map". Genetic diseases may not only be visible at birth, but gene 
manipulation may be able to decrease the occurrence of possible problems such as 
coronary artery disease. But there is the possibility that the gene associated with high 
blood cholesterol may be linked to some other desirable trait. It is possible that if we 
decrease the prevalence of these genes, that we may lose a valuable component of human 
capital ifthe numbers of such people declined. [12] 
By being able to identify the genome of each individual, our society as a whole may 
change drastically. The future may hold many options that seem almost unimaginable to 
the common person today. It would be possible to have services such as computer dating 
that matches genetically compatible people together, or for the government to offer tax 
incentives to couples that have their profiles validated before they reproduce. Even with 
today's technology, it would be possible to take a sample from a napkin or a stray hair to 
have it tested before furthering a relationship. What about insurance policies? Will it 
someday be legal for an insurance representative to request a DNA analysis before they 
will provide coverage? Will our society ever get an extreme such as the movie Gattica 
portrays, where only the "elite", the genetically altered humans, \Vill hold high-powered 
jobs and discrimination is based off of our personal genomes? This is probably not going 
to happen. The first few examples may come to age, but most likely, all genetic mapping 
will be strictly controlled. There are many laws that are in place and will be created to 
provide protection to individuals based on privacy. 
Like any other economic eras, the bio-economy will provide new jobs and careers to 
support this new technology. There will many new branches of Law that are needed to 
provide protection to peoples rights and maintain control over the uses of genetic 
information. As mentioned before, many new branches of science are already being 
developed to study and maintain biotechnology. Law enforcement is already regularly 
using this technology to identify suspects involved in crime scenes. The agricultural 
industry has already embraced some of the early advantages of using biotechnology to 
produce stronger, healthier products. And the pharmaceutical industry is rapidly changing 
to adapt this new technology into useful products. 
Genomics offers us the ability to create drugs that are more precise, safer and that have 
fewer side effects. There are four critical factors in new drug development: the 
bioavailibility of the drug in the system, how quickly it is metabolized, its toxicity, and 
whether after all the pre-clinical test, it is effective in the human system. [13] These 
issues make developing and marketing new drugs very expensive and time consuming. 
The fact is, most drugs being discovered now, won't be tested in humans until 2005 and 
wont be available on the market until 2010. [14] The future of genomic technologies will 
provide for "mass customizing" as stated by Stan Davis in Lessons from the Future [15]. 
This will allow there to be mass quantities of very specialized pharmaceuticals available 
on the market. 
It is estimated that the current genomics market of $1.1 billion will steadily grow to $10.6 
billion by the year 2010 [14], and we are still just in the beginning of this new era. This 
industry has great potential to create a new way of life for every human being on this 
planet. These changes will affect our culture and our day-to-day activities, regardless of 
your opinions about biotechnology. Our understanding about ourselves and every other 
biological thing around us will change significantly over the next few decades. The 
potential of this new era is well beyond any of our best guesses. 
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